A 20 year old fully vaccinated boy who had both shots of Bexsero(R) [Novartis], recommended against meningitis for people 10-25 years, has been discharged from the hospital in CA after coming down with the disease which is fatal in 10-15% of those who develop it.
Some of the noteworthy absurdities in this story* followed by the comments of Rima E. Laibow, MD, Medical Director of the Natural Solutions Foundation, www.DrRimaTruthReports.com, include the following:
“The vaccine was approved by the Food and Drug Administration (FDA) a year ago, under an accelerated process, says Dr. Cody Meissner, a pediatrics professor at Tufts University School of Medicine and consultant to the Advisory Committee on Immunization Practice”
Dr. Rima responds:
The accelerated process referred to does not include the legally required long term studies on efficacy or safety. Both are required under US law before a vaccine can be legally deployed so approval by the FDA and ACIP are not very comforting endorsements.
Advisory Committee on Immunization Practice (ACIP) members and policies have repeatedly been cited by such agencies as the Government Accountability Office (GAO) of the United States for Fraud, Conflict of Interest and other criminal irregularities.
The vaccine contains Neisseria Meningitidis Serogroup B Nhba Fusion Protein Antigen, Neisseria Meningitidis Serogroup B Fhbp Fusion Protein Antigen, Neisseria Meningitidis Serogroup B Nada Protein Antigen and Neisseria Meningitidis Serogroup B Strain Nz98 254 Outer Membrane Vesicle (all foreign proteins injected to bypass the normal immune response to them and the highly inflammatory adjuvant, Aluminum Hydroxide. In addition, it contains Sodium Chloride, Histidine, Sucrose and Water. I assume the water is not fluoridated and would thus be safe to inject with the sodium chloride (salt). Everything else is horrifyingly toxic.
“The vaccine was developed in a new way, a “terrific accomplishment” technologically, Meissner said. But because of the shortened approval process, much is not known about it. “We don’t know if it impacts herd immunity,” he says, in reference to vaccinating enough of a population to keep a disease that crops up from spreading. “We don’t know how long immunity lasts. Is it a few years? Five years? Ten years?””
Dr Rima responds:
Although the development of the vaccine may have been a “terrific accomplishment” so was the development of the hydrogen bomb. Terrific accomplishments are not necessarily good for health although they usually involve a lot of money changing hands.
As Dr. Messinger admits, “we don’t know a lot about it”. When he says “we don’t know if it impacts herd immunity” he is using ‘provax speak’ for “we have no idea if anyone is protected by this vaccine” because IF the now dis-proven theory of herd immunity were real (which is it absolutely NOT in humans) the provaxers would be confident in asserting that this vaccine impacts herd immunity.
If the ACIP does not know how long immunity lasts (assuming there is any) and the vaccine was hastily approved, why inject it into anyone?
Well, perhaps this provides a key to that question:
“ this vaccine is expensive, more than $300 for the series. Meissner published and analysisin Feb 8, 2016 edition of JAMA** spotlighting the challenges of providing such an expensive vaccine for such a rare disease. As many as 350,000 adolescents would need to be vaccinated to prevent one case of disease, he wrote.” [Emphasis added by the author]
Stay with me here, this could get a bit technical.
Here is what Dr. Meissner wrote Italics) with my comments interleaved:
Dr. M: The individual, societal, and economic benefits of disease prevention resulting from childhood and adult immunization programs in the United States are without question.
Dr. Rima: No, they are not. Not a single disease has ever been prevented with a vaccination program. As I showed definitively in my paper*** ONLY clean water, nutrition, hygiene and sanitation have reduced the morbidity and mortality of any infectious disease. The vaccines actually slow or reverse mortality declines!
Dr. M: “[Vaccinating all babies born in 2009 will require vaccine purchases of between] $7.8 billion, based on CDC costs, and $11.6 billion at private sector pricing.” [Emphasis added]
Dr. Rima: For which we get an astonishing number of meaningless, but dangerous vaccinations (all toxic) for no benefit to us, but a huge one to the vaccine manufacturers. Here is what Dr. M has to say about the relationship between cost and any possible benefit even assuming that the vaccine might work, as it failed to do in the case of the young man mentioned at the top of this article: “A recommendation for routine immunization at 11, 16, or 18 years of age to align with existing meningococcal quadrivalent (serogroup ACWY) conjugated vaccine recommendations optimally could prevent approximately 15 to 29 cases of serogroup B and 2 to 5 deaths annually.” [Emphasis added]
He goes on to state, I would imagine with a straight face, “Approximately 100 000 to 350 000 adolescents would require vaccination with serogroup B vaccines to prevent 1 case, and 600 000 to 2.3 million persons would require vaccination to prevent 1 death.” [Emphasis added]
Dr. Rima: Run that by me again? Assuming that the vaccine works, we would need to vaccinate, toxify, expose to various harms with an unavoidably unsafe, untested, rushed-to-market vaccine between 600,000 and 2.3 million people to [theoretically] prevent 1 death if the vaccine prevents any deaths at all? Right. That’s exactly what the good doctor wrote.
At just what cost in dollars and cents? Good question! Let’s see what Dr. Meissner has to say on that score: “The cost per QALY [ quality-adjusted life-year saved] for either of the 2 serogroup B vaccines routinely administered at 11 through 18 years of age (including college students) is between $3.7 million and $9.4 million, figures more than 25-fold higher than for routinely recommended vaccines.” [Emphasis added].
Dr. Rima: What does QALY, this metric that balances health and cost, actually correspond to? Here is what Dr. Meissner says: “QALYs are intended to assist in resource allocation between competing patient groups and to assist policy makers and physicians as they address the issue of where to assign limited resources to generate maximum health care benefit. However, application of this cost-effectiveness ratio is hindered by a lack of consensus on what constitutes an acceptable threshold, with most suggestions ranging from $50 000 to $200 000/QALYS.“
Dr. Rima: What that means is that QALY is a totally made-up metric with neither consensus nor data to support it. But health care decisions, affecting, or afflicting your life are made on the basis of this fairy dust.
Here is what Dr. M has to tell us about the risk of meningitis in the US: “In 2014, there were 433 cases of all-serogroup–invasive Neisseria meningitidis reported in the United States among all ages. Among the cases in which serogroup was known, 38% were caused by serogroup B….
However, serogroup B is not contained in the meningitis vaccines recommended for routine use beginning at 11 years of age. Two novel serogroup B protein vaccines have been licensed for use in persons 10 through 25 years of age” including the Novartis one which failed to protect the youngster above.
These new vaccines are not mandates since they carry a Level B permission.
So, in essence, we have
- A rapidly developed, rushed-to-market vaccine for
- A disease that poses no meaningful threat which is
- Exceedingly expensive providing billions of dollars of uninsurable profit but which
- Provides only hoped-for protection and which
- Requires millions of people vaccinated to prevent even one death at billions of dollars of expense
Another fraudulent attempt on your life, your pocketbook, your immune system and your rational thought.
To say no to all vaccines, the position recommended and supported by Dr. Rima and the Natural Solutions Foundation, visit www.DrRimaTruthReports.com/AdvanceVaccineDirective.
**Meisner, H. C, Immunization Policy and the Importance of Sustainable Vaccine Pricing, JAMA. Published online February 08, 2016. doi:10.1001/jama.2016.0469